ARTES receives French Research Tax Credit (CIR) Accreditation
ARTES Biotechnology GmbH today announced that it has just obtained governmental approval for 'Crédit d'Impôt Recherche' (CIR) for a three-year period from the French Ministry of Higher Education and Research (MESR)
(PresseBox) - The French R&D tax credit CIR gives French companies the ability to claim tax relief on 30% on all generated costs outsourced to ARTES? R&D services.
?We are pleased to receive this accreditation and to be approved as valid and reliable R&D provider from the French Ministry?, Dr Michael Piontek, Managing Director of ARTES. ?It allows our customers in France to benefit from tax relief of their R&D expenses committed to us and it will help us to tie up our relationships with our present clients in France and to install new collaborations?.
ARTES Biotechnology is globally active as R&D company specialized in developing biopharmaceutical and vaccine production processes.
The company operates worldwide from its 850m2 S1 facilities in Langenfeld, from where it also offers cell line engineering based on yeast (Hansenula polymorpha) and bacterial (E. coli and Bacillus) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support
ARTES is a pharmaceutical technology provider specialized in recombinant protein production, process and vaccine development from microbial expression systems and markets the unique METAVAX® (dHepB-VLP) technology in combination with yeast expression. ARTES platform is applicable for large and multimeric antigens and is able to create chimeric VLPs. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850-sqm S1 facilities in Langenfeld..
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
ARTES is a pharmaceutical technology provider specialized in recombinant protein production, process and vaccine development from microbial expression systems and markets the unique METAVAX® (dHepB-VLP) technology in combination with yeast expression. ARTES platform is applicable for large and multimeric antigens and is able to create chimeric VLPs. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850-sqm S1 facilities in Langenfeld..
Datum: 24.10.2017 - 04:38 Uhr
Sprache: Deutsch
News-ID 1525511
Anzahl Zeichen: 3025
contact information:
Contact person:
Town:
Langenfeld
Phone:
Kategorie:
Handcrafts
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 1290 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ARTES receives French Research Tax Credit (CIR) Accreditation
"
steht unter der journalistisch-redaktionellen Verantwortung von
ARTES Biotechnology GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
